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Abstract. A within-host mathematical model to describe the dynamics of target 
cells and viral load in early HIV-1 infection was developed, which incorporates a 
combination of RTI and PI treatments by using a pharmacokinetics model. The 
local stability of uninfected steady state for the model was determined using an 
alternative threshold. The pharmacokinetics model was employed to estimate 
drug efficacy in multiple drug dosing. The effect of periodic drug efficacy of 
pharmacokinetic type on outcome of HIV-1 infection was explored under 
various treatment interruptions. The effectiveness of treatment interruption was 
determined according to the time period of the drug holidays. The results showed 
that long drug holidays lead to therapy failure. Under interruption of treatments 
combining RTI and PI therapy, effectiveness of the treatment requires a short 
duration of the drug holiday.  
Keywords: CD4+T cells; drug holiday; HIV-1; Langerhans; pharmacokinetics. 
1 Introduction 
The human immunodeficiency virus type 1 (HIV-1) is a retrovirus that infects 
the cells of the immune system expressing receptor CD4 and co-receptor CCR5 
on their surfaces [1]. When HIV enters into the individual’s body via epithelium 
mucosa, it attacks target cells such as Langerhans cells and CD4+T cells in the 
genital mucosal. The spread of the HIV infection in the genital tract can occur 
through cell-to-cell contact or virus-to-cell contact [2]. 
Highly active anti-retroviral therapy (HAART) is one of the HIV treatment 
strategies that is effective through suppressing the viral load. It has a 
combination of one or more reverse transcriptase inhibitors (RTIs) as well as 
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protease inhibitors (PIs). RTI drugs prevent infection of target cells, while PI 
drugs prevent active infected target cells from producing infectious virus 
particles [3].  
A number of in-host HIV-1 infection dynamic models have been developed to 
study the effects of antiretroviral (ARV) therapy and theoretically associating it 
to the development of treatment strategies for HIV-infected individuals [4-10]. 
A simple dynamic model of RTI monotherapy was proposed by Srivastava, et 
al. [6], classifying the infected CD4+T cells into two categories, namely the 
class of infected CD4+T cells in the process of acquiring a pre-RTI drug and the 
class of infected CD4+T cells having fully acquired the RTI drug. Their results 
suggested that the HIV infection is cleared when the drug efficacy exceeds a 
critical value. De Leenheer [7] employed a standard model incorporating 
treatment by using a piecewise constant periodical signal to approximate drug 
efficiency. The results of the study showed that HIV infection is cleared more 
quickly when the drug is more efficient and effective over a longer time period. 
A similar model incorporating RTI and PI therapies is proposed in [8] in order 
to assess the impact of therapy on the dynamics of the disease due to imperfect 
adherence and emergence of drug resistance to the treatment regime. The 
efficacy functions were modeled by bang-bang and single-dose pharmacokinetic 
type. The average drug efficacy formulated from the single-dose 
pharmacokinetics model was used to investigate the outcome of HIV infection 
during ARV treatment under different scenarios. The results of the study 
suggested that PIs are more efficient than RTIs when used as monotherapy and 
that a combination of RTIs and PIs is more effective than monotherapy. Using a 
simple model of ARV therapy with constant efficacy, Perelson [10] revealed the 
dynamics of the HIV viral load and provided insight in the development of drug 
therapies. The study focused only on CD4+T cells as target cells for HIV. 
Chirove, et al. [11] have proposed an in-host HIV-1 infection model that 
captures the interaction between the free virus, Langerhans cells and CD4+T 
cells during early HIV infection. The results from their study showed that viral 
degradation slows down the progression of the HIV infection, whereas viral 
lysis increases the HIV infection. Sutimin, et al. [12] modified the model in [11] 
to incorporate a combination of RTI and PI drugs administered periodically. For 
periodical drug dosing, a pharmacokinetics profile of the drug concentration 
was used by considering steady state pharmacokinetics. The results from the 
study suggested that suboptimal adherence and drug resistance cause treatment 
failure. 
More realistic models need to capture drug efficacy as a function of periodic 
pharmacokinetics with multi-dosing. This enables one to realistically capture 
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drug accumulation in the plasma before administering the next dose. 
Pharmacokinetics of drugs in the body during drug administration varies over 
time due to the processes of drug absorption, distribution and metabolism in the 
body, which take place at variable rates [13]. Thus, the drug concentration in the 
body is also determined by the drug content in the body before administering 
the drug for the next drug dosing. The continuous uptake of HAART was met 
with a number of challenges. It was proved that there is rapid waning of 
adherence by the patients. This is associated with increased myocardial 
infarction rates, putting individuals at risk of coronary artery disease or 
accelerated liver disease due to metabolic effects of HAART. On the other 
hand, high medical costs impede efforts to increase the efficacy of HAART. 
One of the strategies to avert the aforementioned effects is the introduction of 
drug holidays. There are two types of drug holidays, namely time-dependent 
holidays and CD4 count-dependent holidays. CD4 count-defined holidays have 
been extensively used, whereas little attention has been given to time-dependent 
holidays, even though they have the potential to optimize ARV therapy [14]. 
The safety and efficacy of time-dependent drug holidays still remains to be 
determined. 
Available evidence reflects that HIV transmission occurs on different immune 
cells. Focusing on CD4+T cells only may underestimate the actual impact of the 
HIV infection. Furthermore, various transmission mechanisms of infection such 
as cell-to-cell transmission also contribute to HIV invasion of the immune 
system [2,9]. 
In this paper, we use the model from [12] and emphasize the importance of 
using pharmacokinetics as a realistic way to capture the effects of RTIs and PIs. 
Unlike in [12], our objective was to investigate the impact of multiple drug 
dosing, incorporating drug accumulation with drug holidays in combined RTI 
and PI therapies on HIV-1 infection. We considered that the drugs are only 
effective on wild-type virus and do not take into account drug-resistant mutant 
strains, mutants due to copying errors, or mutants due to the virus changing its 
genome. We have carried out analysis of the uninfected steady state and 
investigated numerically the consequences of different treatment scenarios and 
their impact on the evolution of both the host cells and the free virus.  
2 Model Incorporating Combined RTI and PI Treatment 
We used the model from Sutimin, et al. in [12], introducing the following 
modifications: (i) introducing RTI and PI treatments in multiple drug dosing 
with drug holidays, and (ii) introducing additional viral production by 
Langerhans cells and death of Langerhans cells due to viral lysis. Each 
population of the target cells is divided into two subclasses that do and do not 
4 Sutimin, et al. 
react to drugs, a scenario clarified by the hapten and p-i concepts on drug action 
and drug reaction by immune cells [15,16]. The model involves nonlinear ODEs 
of state variables relating to the populations of susceptible Langerhans cells (L) 
that do not react to active drugs, susceptible CD4+T cells (T) that do not react to 
active drugs, susceptible Langerhans cells in the process of acquiring active 
drugs (Ld), susceptible CD4+T cells with active drugs (Td), infectious 
Langerhans cells (Li), infectious CD4+T cells (Ti), and the free virus (V). The 
model is given as follows:  
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The parameters of RTI  and PI   0 , 1RTI PI    represent RTI and PI drug 
efficacies, respectively, where RTI  (0 1)   is the effectiveness of RTI in 
preventing the infection of Langerhans cells due to the longer-lived infection 
and the more complex infection pathways of Langerhans cells compared to 
CD4+T cells [2,17].  
Eqs. (1) and (2) describe susceptible Langerhans and CD4+T cells. We assume 
that they are produced in the body at constant rates λl and π, respectively. HIV 
infection of Langerhans cells is inhibited by the degradation mechanism in the 
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Langerhans cells with half-saturation constant A. The Langerhans and CD4+T 
cells diminish by natural death at constant rates μl and μ, respectively. 
Susceptible Langerhans cells can be infected by the free virus and by infected 
Langerhans and infected CD4+T cells at constant rates β1, β2, respectively. 
Healthy CD4+T cells can be infected by infected Langerhans cells, by infected 
CD4+T cells and by the free virus at constant rates β3, β4, β5 respectively. We 
used a mass-action type model to describe the infection of CD4+T cells by 
infected Langerhans cells, infected CD4+T cells and the free virus.  
Once the treatment has started, susceptible Langerhans and CD4+T cells that 
acquire active drugs move to new classes Ld and Td at constant rates σ1 and σ2, 
respectively. Eqs. (3) and (4) describe the populations of Langerhans and 
CD4+T cells that acquire active drugs. They diminish due to natural death at 
constant rates μl and μ, respectively. Once target cells acquire the active drugs, 
the infection rates of the Langerhans cells caused by the free virus, and by both 
infected Langerhans and infected CD4+T cells are reduced to 1 (1 )R T I    and
2 (1 )R T I   , respectively, due to the effect of the drugs preventing the 
infection of target cells. The infection rates of susceptible CD4+T cells caused 
by infected Langerhans cells, by infected CD4+T cells and the free virus are 
reduced to 3 (1 )RTI   , 4 (1 )RTI    and 5 (1 )RTI   , respectively. We assume that the 
populations of target cells (i.e. Langerhans and CD4+T cells) with active drugs 
grow proportionally to the number of each healthy target cell with a constant of 
proportionality σ1 (for the Langerhans cell population) and σ2 (for the CD4+T 
cell population). 
In Eq. (5), the population of infected Langerhans cells is produced from both 
susceptible Langerhans cells and Langerhans cells in the process of acquiring 
active drugs that become newly infected cells. It diminishes due to the natural 
and viral lysis death at constant rates μl, ρ, respectively. In Eq. (6), the 
population of infected CD4+T cells is generated from both susceptible CD4+T 
cells and CD4+T cells with active drugs that become newly infected cells, and diminishes due to natural and viral lysis death at constant rates μ, α, 
respectively. Eq. (7) describes the free virus population. The death of target 
cells due to viral lysis induces the free virus production of infected target cells 
that supplies the free virus population. Once the target cells acquire active 
drugs, the average of the infectious virus production by actively infected CD4+T 
cells and infected Langerhans cells is reduced to (1 )P I N    and (1 )P I M    respectively, due to PI drug action in blocking infectious virion production. The 
free virus population decreases due to degradation of healthy Langerhans cells 
and Langerhans cells with active drugs at constant rate ϕ, and it dies at constant 
rate μv. 
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3 Model Analysis  
We recall that the basic reproductive number, 0,  is the average number of 
secondary infections of target cells that are generated when one infected cell or 
virus is introduced into a susceptible cell population. The next generation 
matrix [18] of the model Eq. (1) – Eq. (7) is given by 
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
    . The basic reproduction number 0  is 
defined as the spectral radius of G. The threshold number 0  cannot be 
obtained from the analytical calculation. Thus, we estimate this number using 
an alternative reproduction number 1  that provides a significant biological 
interpretation. The characteristic polynomial of matrix G is 
3
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Following the analysis in [11], the parameter 1 , where 1 0  , as an 
alternative reproduction number is determined from F(X) = 0 that satisfies F(1) 
= 0. By defining 21 1 0A A   , the quantity 21  can be represented as a linear 
combination of four cycles of infection as follows, 
 21 ,i i i i i i ii i i iT V T T L T T LV L T T V T              (9) 
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where   4 51 2
1
i i
PI
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v
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We note that the quantities
1
1

,
2
1

 represent the average time periods when 
actively infected CD4+T cells and actively infected Langerhans cells spread the 
virus, respectively. These quantities should be positive values, thus we assume 
that the quantities 1 2,   are positive.  
As described in [11], the sub-reproduction number, 
i iT V T  , is the cycle of 
infection that interprets the average number of newly infected CD4+T cells generated by an infected CD4+T cell that replicates new infectious virus 
particles (affected by blocking of PIs). Subsequently, viruses infect the 
susceptible CD4+T cells to become newly infected CD4+T cells. The sub-
reproduction number 
i i iT L T   interprets the average number of new infections 
of target cells propagated by one infected CD4+T cell that infects susceptible 
Langerhans cells to become newly infected Langerhans cells (due to the RTI 
drug not being responded by all target cells). Next, these infected cells transmit 
the infection to susceptible CD4+T cells to become the new infections of CD4+T 
cells. The sub-reproduction number, 
i i iT V L T   , interprets as the average 
number of newly infected target cells caused by one infected CD4+T cell that 
replicates new infectious virus particles (affected by PI blocking), which infect 
susceptible Langerhans cells to create new infections of Langerhans cells. In 
turn these infected Langerhans cells infect susceptible CD4+T cells to create 
new infections of CD4+T cells. 
i ii V TT L   , interprets as the average number of 
newly infected target cells caused by one infected CD4+T cell that infects 
Langerhans cells producing infectious virus particles, where these viruses infect 
other Langerhans cells to become newly infected Langerhans cells that produce 
viruses. In turn these viruses infect susceptible CD4+T cells becoming new 
infections of CD4+T cells. In the next section, we show the use of the alternative 
reproduction number to analyze the local stability of the uninfected steady state 
of the model. Unlike in [11], the additional drug active classes make the 
computation of the endemic equilibrium point complicated and difficult to 
express in closed form. We used the instability conditions of the disease-free 
equilibrium to infer the existence of the endemic equilibrium point. 
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3.1 Stability of the Uninfected Steady State 
When the virus is not detected in the plasma or fully suppressed in the body 
during ARV treatment, the system possesses an uninfected steady state. The 
uninfected steady state of the model is given by 
0 00 00 ( , ,0, , ,0,0)d dE L L T T . This 
disease-free status is typical of the virus being suppressed below detection while 
the individual still has to take drugs for protection. Otherwise, when the drug is 
stopped the individual may actually get to a completely disease-free, drug-free 
state or return to the endemic status where virus, infected Langerhans cells and 
infected CD4+T cells are present in the body. We analyze the stability of the 
disease-free equilibrium for the model. The following theorem expresses the 
local stability of 0E  that is determined by threshold number 1 . 
Theorem 3.1 The disease-free equilibrium 0E  is locally asymptotically stable 
when 1 1   and 1 2   , and unstable when 1 1  .  
Proof. The Jacobian matrix of the model Eq. (1) – Eq. (7) at 0E , 0( )J E  is given 
by 
1 2 2 1
2 3 0 4 0 5 0
1 2 1 2 1 1 1
2 3 0 4 0 5 0
2 2 3 1 3
3 4 1 5 4
2
0 0 0
0 0 0
0 0 ( 1) ( 1) ( 1)
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    
  
  
 
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The eigenvalues of 0( )J E  are 1 2 3 2, , ( ),l             4 1( )l     , the 
others satisfy the equation 
 3 22 1 0 0a a a       (10) 
 2 2 1 2va       ,    20 2 1 2 11 ,va          
       2 2 1 21 2 1 1 2 1 2 1
2 2
1 1v
v
z z
a                    
,  
      2 4 5 2 1 3 3 3 1 1 2 5 41 1PI PIN Mz                    ,  
     1 3 4 2 3 2 1 3 5 21v PIz N M                 +   1 2 3 11 PI M     .  
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We see that 2 0,a  0 0a   if 21 1  . Next, we prove that 2 1 0 0a a a  . By 
manipulating the calculation for the condition 2 1 0a a a , we obtain that 
       2 21 2 0 1 2 1 2 2 2 11v va a a                   +  
   2 1 2 22 2 2
2 2
v
v
a z a za           . 
It is clear that 2 1 0 0a a a   when 21 1   and 1 2   . The Routh-Hurwitz 
stability criteria are satisfied if 21 1  and 1 2   . We note that for 
10 ,   we have 
2
1 1   if 1 1.   Thus the disease-free equilibrium is 
locally asymptotically stable if 1 1   and 1 2   . On the other hand, if 
1 1   then 21 1  . This implies that 0 0a  . When 0 0a  , there is one sign 
change in Eq. (10). By Descartes’ rule of signs, there is exactly one positive 
zero of Eq. (10). We conclude that there is exactly one positive eigenvalue if 
1 1  . Thus the disease free equilibrium is unstable if 1 1  .  
In the next section, we study the drug pharmacokinetics in the body when the 
drug is administered periodically and orally, and also formulate the drug 
concentration as a periodic function of the pharmacokinetics model.  
3.2 Time-varying Drug Efficacy of Multiple Dose Pharmaco-
kinetics 
Pharmacokinetics is the concept that explains the kinetics of absorption, 
distribution and elimination of drugs inside the body. We describe the plasma 
concentration of the drug assuming that the body is a one-compartment model. 
In dosing the drug orally, the drug concentration in the body rises rapidly, 
which is characterized by absorption and distribution in the body. After 
achieving its maximum, it decreases slowly due to elimination from the body 
[3,19]. We define the drug concentration in an initial single dose as follows, 
 
    
   
max
max
max
max
max max
(0) 1(0) , 0,( ) 1
, ,
t
T
k t T
C C e
C t T
C t e
C e t T 


 
   


 (11) 
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where  is the drug dosing interval, 1/2t  is the serum half-life, 
1/ 2
ln(2)k t , and 
maxT  is the time when the drug achieves peak concentration. In multiple dosing, 
the drug concentration in the body at the next dose is higher due to drug 
accumulation from previous doses. We use the concentration function in Eq. 
(11) to formulate the drug concentration in the body in multiple dosing. By 
using the superposition principle, the actual drug concentration in the body in 
the th( 1)n   dosing cycle, 0,1, 2, 3, ...n   is given by ( ) ( ) ( )n n nC t t F t   , where 
    m ax( )m ax e 1 e , [ , ( 1) ]1 e
k T nk
n k
C
t t n n
 
  
  

     ,  
 
      
    
max
max
max
max
max max
(0) 1(0) , ,( ) 1
, , 1
t n
T
n
k t n T
C C e
C t n T n
F t e
C e t T n n


 
 
 

  
    
  

. 
We define the drug efficacy function [19] as     50
C t
t
IC C t
 
, where  C t  is 
the drug concentration and IC50 is the drug concentration required for inhibiting 
viral replication by 50%. 
The concentration and efficacy evolutions for each RTI and PI drug in the body 
in multiple drug dosing are presented in the next section.  
4 Simulation Results  
We performed numerical simulations to describe the implications of RTI and PI 
treatments modeled by pharmacokinetic type with respect to the dynamics of 
free virus load, Langerhans and CD4+T cells for early HIV-1 infection.  
Table 1 Pharmacokinetic parameters (cf. [8]). 
Drugs Dosage Cmax (μM)  
Tmax 
(h)  
t1/2 
(h)  
IC50 
(μM)  
RTIs      
DLV 400 mg,12 h 35 1.3 3.3-8.3 0.001-0.69 
EFV    600 mg, 24 h 12.9 3-5 52-76 0.001-0.11 
NVP  200 mg, 24 h 5.58 4 16.5 0.01-0.1 
PIs 
APV 
IDV 
RTV 
 
1,200 mg, 8 h 
800 mg, 12 h 
600 mg, 12 h 
 
20.7 
12.63 
11.2 
 
1-2 
0.8 
2-4 
 
7.1-10.6 
1.5 
3-5 
 
0.012-0.08 
0.025-0.08 
0.0038-0.154 
Note: DLV: delavirdine, EFV: efavirenz, NVP: nevirapine APV: aprenavir, IDV: indinavir, RTV: 
ritonavir. 
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In this section, we explore the outcomes of the effects of structured treatment 
interruption (drug holidays) in varying strategies. Firstly, we present the 
evolution of the concentration and efficacy of both RTI and PI drugs under 
perfect adherence in accordance with the recommendations. Secondly, we 
illustrate the time course of the concentration and effectiveness of both RTI and 
PI during continuous drug administration followed by a 1-day drug holiday. 
Thirdly, we investigate numerically the outcomes of combined RTI and PI 
drug-holiday treatments for various scenarios in drug administering during 160 
days. The values of the pharmacokinetic parameters are given in Table 1. The 
parameter values of the model were taken from [11] and are given in Table 2. 
Table 2 Parameter descriptions of the model. 
Parameters Descriptions Values Units Sources 
λl Production rate of Langerhans cells (100,110) cells/day [11] π Production rate of CD4+T cells 103 cells/day [22] 
A The half-saturation constant of the infection process in Langerhans 1500 cells/mm
3 [11] 
μl Natural death rate of Langerhans cells (0.111,0.333) 1/day [23] 
μ Natural death rate of CD4+Tcells 0.1 1/day [24] 
μv Natural death rate of free virus 2.4 1/day [26] 
σ1,σ2 The constant rates of target cells acquiring the drugs (0,1) 1/day varies 
β1 Langerhans infection rate by free virus. (0.0094,0.156) 1/day [25] 
β2 Langerhans infection rate by infected cells. (0.0001,0.02) 1/day [11] 
β3 CD4
+T cells infection rate by 
infected Langerhans cells. (0.0001,0.01) 1/day [11] 
β4 CD4
+T cells infection rate by 
infected CD4+T cells. (0.00001,0.01) 1/day [11] 
β5 CD4
+T cells infection rate by free 
virus. (2x10
-5,0.005) 1/cells day [27,28] 
ϕ Constant degradation rate by Langerhans cells (2,9) 1/day [29, 30] 
α Constant lysis death rate of CD4
+T 
cells 0.24 1/day [22] 
ρ Constant lysis death rate of Langerhans cells 0.025 1/day [34] 
δ Ratio of infection in CD4
+T cells to 
infection in Langerhans cells. (0.3,1) - [2] 
N The average number of virions produced by infected CD4+T cells (100,1000) 
virions/ 
cells day 
[31,32, 
33] 
M The average number of virions by infected Langerhans cells 
63.5 
(10,100)  
virions/       
cells day 
[34] 
[35] 
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Langerhans cells endocytose HIV-1 into cytoplasm for several days, from 1 day 
up to 3 days, leading to Langerhans infection, while infection of CD4+T cells 
occurs in 1 day [2]. Parameter   is computed as the ratio of time duration of 
infection of CD4+T cells to the duration of infection of Langerhans cells. The 
value of  ranges from 1/3 to 1. In the simulations we chose 1  . 
The initial conditions for the simulations were T(0) = 850 cells/mm3 Ti(0) = 41 
cells/mm3, V(0) = 3.76 virions/mm3 [36], and we chose Td(0) = 0 cells/mm3. The 
number of healthy Langerhans cells in an HIV-infected individual is 685 up to 
1600 cells/mm3, whilst the proportion of infected Langerhans cells is 5% up to 
25% of Langerhans cells [37,38]. In the simulations we chose L(0) = 850 
cells/mm3, Li(0) = 50 cells/mm3, and Ld(0) = 0 cells/mm3. 
 
Figure 1 Time evolution of concentration and efficacy of RTI and PI drugs. 
Figure 1 shows that in RTI class, the concentration of delavirdine reached the 
steady state condition after a longer time compared to the other drugs. In the PI 
class, the amprenavir concentration achieved the steady state condition after a 
longer time period compared to the other drugs. We see that efavirenz had 
higher effectiveness compared to delavirdine, despite the fact that the 
concentration of efavirenz was lower. In Figure 2, we observe the outcomes of 
treatment interruption of both RTI and PI associated with their concentration 
and effectiveness. In this case, we consider the cycles of treatment involving 5 
days continuous treatment followed by a 1-day drug holiday. 
Figure 2 shows that, in the RTI class, the effectiveness of efavirenz decreased 
more quickly compared to the other drugs, whilst in the PI class, the 
effectiveness of indinavir decreased more sharply compared to the other drugs.  
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Figure 2 Time evolution of the concentration and effectiveness of RTI and PI 
drugs in 5 days on and 1 day off drug administration. 
 
Figure 3 Evolution of Langerhans,  cells and free virus over time when 
delavirdine and ritonavir drugs were administered in a drug holiday treatment, 
with A = 1500, π = 103, λ1 = 105, μ = μl = 0.1, μv = 2.4, σ1 = σ2 = 0.2, ϕ = 2, β1 = 0.01, β2 = 0.002, β3 = 0.0005, β4 = 0.0001, β5 = 0.00042, α = 0.24, ρ = 0.025, δ = 1, N = 350, M = 50. 
Next, we studied the outcome of ARV therapy under different drug-holiday 
strategies in drug administration during 160 days. The average drug holiday of 
the different treatment strategies was about 24 days. The treatment scenarios 
can be described as follows. Firstly, therapy involving cycles of treatment with 
CD4 T
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a combination of delavirdine and ritonavir administered continuously for 5 days 
followed by a 1-day interruption. Secondly, therapy involving cycles of 
treatment with a combination of delavirdine and ritonavir administered 
continuously for 10 days followed by a 2-day interruption. Lastly, treatment 
with a combination of delavirdine and ritonavir administered continuously for 
20 days followed by a 4-day interruption and the cycle of the treatment being 
repeated continuously. 
Figure 3 shows that in the treatment cycles involving a 1-day interruption, the 
number of healthy target cells still increased. The treatment cycles involving a 
4-day interruption led to the number of healthy target cells decreasing rapidly 
with oscillations (see Figure 3(a) and Figure 3(b)). The decrease is associated 
with the increase of the number of infected target cells and of the free virus in 
an oscillatory manner (see Figure 3(c) and Figure 3(d)). 
5 Conclusion  
In this paper, the impact of multiple drug dosing incorporating drug 
accumulation with drug holidays in combined RTI and PI therapies on HIV-1 
infection was investigated. A model incorporating some of the target cells for 
HIV encountered during early HIV infection, i.e. Langerhans cells and CD4+T 
cells was constructed. Mathematical analysis of the infection-free equilibrium 
point was done using an alternative threshold that provided conditions under 
which the infection may progress, i.e. when the infection-free equilibrium is 
unstable. This instability condition was used to come up with a representative 
scenario of infection progression and under this scenario we numerically 
investigated the outcomes of drug-holiday treatments in early HIV-1 infection 
considering that the drugs are administered orally and periodically. A 
pharmacokinetics model was used to calculate the drug efficacy of RTI and PI 
drugs as a periodic time-varying function. The evolution of the drug 
concentrations for multiple drug dosing was modeled more realistically by 
considering the drug accumulation in the body before the next dose was 
administered. 
Also, the drug pharmacokinetics were modeled to formulate the drug 
concentration in the body and the effects of various treatment regiments on the 
outcome of early HIV-1 infection corresponding to the number of Langerhans 
cells, CD4  T cells, and viral load. It is important to know the time duration of 
the drug holidays during ARV therapy. Our results provide insight for 
administration of drugs using drug-holiday strategies during early HIV 
infection. Our results suggest that periodic drug holidays are more effective if 
the time duration of the drug holidays is shorter, when the drugs are 
administered continuously for 5 days followed by a 1-day interruption. Our 
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results are supported by other studies, such as [20], although the authors 
recommend 5-day on and 2-day treatment interruptions. Benson [21] suggests 
that safe treatments may require short interruptions, although he does not 
specify precisely what duration of interruption. The concept of periodic drug 
efficacy according to pharmacokinetic type provides insight into ARV therapies 
in prognosis of HIV-1 infection. This study can be further developed to explore 
the optimum control problems, including structured treatment interruptions, as 
an important strategy for antiretroviral therapy to suppress virus replication.   
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